| Oncolytics Ready for Final Clinical Step With Reolysin Bio Tuesday submits: After a 10-year journey, Oncolytics Biotech (TSX:ONC (2.81 ↑0.00%); (NASDAQ:ONCY) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when we started out,” CEO Dr. Brad Thompson said in an exclusive interview with BioTuesday.ca.Complete Story » seekingalpha.com |
Human Genome Sciences' Latest Cancer Drug Disappoints Zacks.com submits: Recently, Human Genome Sciences, Inc. (HGSI) announced disappointing results from a mid-stage study which evaluated its candidate mapatumumab (HGS-ETR1) in conjunction with Takeda’s bortezomib (Velcade) for treating patients suffering from advanced multiple myeloma.The data from the randomized study did not demonstrate any difference in disease response or progression-free survival rates between patients receiving mapatumumab plus bortezomib compared with those receiving bortezomib alone. The company intends to present complete results from this study in a scientific meeting later this year.Complete Story » seekingalpha.com |
Exelixis, Inc. Q2 2010 Earnings Call Transcript Exelixis, Inc. (EXEL)Q2 2010 Earnings Call TranscriptAugust 5, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Medical Bracelets Go High-Tech New bracelets and other medical-identification systems can fill in first responders on practically a patient's complete health history. They're a far cry from the simple identification bracelets of the past. online.wsj.com |
Clarient, Inc. Shareholder Investigation by Briscoe Law Firm Regarding the Buyout by General Electric Company [Business Wire] - The Briscoe Law Firm, PLLC, founded by a former state prosecutor and enforcement attorney for the United States Securities and Exchange Commission, and the law firm of Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of Clarient, Inc. related to the proposed buy-out of Clarient by General Electric Company. us.rd.yahoo.com |